Trading Update

DXS INTERNATIONAL PLC

Trading Update

The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that the Board is reviewing its growth plans for the next 24 months. The Company is seeking to accelerate its current market expansion drive in both the UK and internationally and to support the launch of its new advanced artificial intelligence clinical decision support solution. The option to achieve a rapid expansion of its customer base may require further investment in its sales, marketing and development base. A further fund raise to increase efforts in this area is under consideration, and ideally the Company would like to raise up to but not limited to £1.5m in this calendar year as a part of those plans, however no firm decisions have yet been made in this regard.

In our recent annual report, we highlighted that healthcare IT is moving at an unprecedented pace. The Covid-19 pandemic has added new impetus to the realisation that healthcare delivery is urgently in need of a major overhaul and DXS, with deep knowledge and experience in the electronic healthcare space, is well-positioned to exploit this fast-emerging opportunity.

A further announcement will be made in due course when plans have been finalised.

The Directors of DXS International plc accept responsibility for this announcement.

Contacts :

David Immelman        01252 719800

DXS International plc

AQSE Corporate Broker

Hybridan LLP        020 3764 2341

Claire Louise Noyce

Corporate Advisor

City & Merchant        020 7101 7676

David Papworth

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.



EN
02/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DXS International PLC

 PRESS RELEASE

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK ...

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare featured in Innovate UK Research Project DXS International plc ("DXS" or "the Company"), a leading provider of digital clinical decision support solutions, is thrilled to announce that its leading-edge digital health solution, ExpertCare, has been independently reviewed by the prestigious York Health Economics Consortium (YHEC) with results that confirm its powerful impact on both clinical outcomes and NHS cost-efficiency.  Funded by DXS and Innovate UK and...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Research: DXS International plc: Experts to Decide

DXS’s ExpertCare, a digital solution platform, is selected for the Grow Digital Health Midlands Programme. This Programme is a collaboration between Health Innovation East and West Midlands, to provide a platform to encourage digital innovation to address the NHS most pressing challenges. DXS will be exposed to the largest NHS England region, encompassing 11 Integrated Care Systems, and a population of approximately 11.8m people. The programme is designed to help UK technology innovators scale p...

 PRESS RELEASE

Company Update

Company Update DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare selected for prestigious Grow Digital Health Midlands Programme DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to announce that ExpertCare, its digital medicine solution, has been selected for the prestigious Grow Digital Health Midlands Programme. Grow Digital Health Midlands - a new collaboration from Health Innovation East Midlands and Health Innovation West Midlands, has announced its first cohort of nine high-potential digital health companies of which DXS and the ...

 PRESS RELEASE

Statement re Grant of Options and Warrants

Statement re Grant of Options and Warrants DXS INTERNATIONAL PLC (AQSE: DXSP) Granting of Share Options and Warrants The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, announces that it yesterday granted share options to a number of directors, employees, and consultants. Most of these options grants are under an Enterprise Management Incentive (“EMI”) scheme and the remainder under an unapproved share option scheme. All these Share Options are at an exercise pric...

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 13 February, Mr Bob Sutcliffe, the Chairman, purchased 30,000 Ordinary Shares in the Company at a price of 2.89p per share. Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 1,333.756 Ordinary Shares representing 2.0...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch